Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Antibiotic > Amoxicillin

Amoxicillin

Amoxicillin is a broad-spectrum penicillin antibiotic used to treat a wide range of bacterial infections.
It is effective against Gram-positive and Gram-negative bacteria, and is commonly used to treat respiratory tract infections, skin and soft tissue infections, and urinary tract infections.
Amoxicillin works by interfering with the synthesis of the bacterial cell wall, ultimately leading to cell death.
It is generally well-tolerated, but can cause side effects such as nausea, diarrhea, and rash in some patients.
Proper dosing and duration of therapy are important to ensure the efficacy and safety of Amoxicillin treatment.
Experiance the power of PubCompare.ai to optimize Amoxicillin dosing and identify the best treatment protocols from research literature.

Most cited protocols related to «Amoxicillin»

1
Systematic Review of Antimicrobial Resistance in Enteric Fever
We conducted a systematic review of published literature between 1990 and 2018 following the PRISMA guidelines (Additional file 1: Table S1) [22 (link)]. The protocol was registered with the international prospective register of systematic reviews (CRD42018029432). The search strategy was devised by an academic librarian (EH). MEDLINE, Ovid Embase, Global Health, Cochrane Library, Scopus, Web of Science-Core Collection and LILACS were searched using a syntax that combined Medical Subject Headings (MeSH) and free text terms for the pathogens of interest (e.g. S. Typhi, S. Paratyphi A, enteric fever) with terms for antimicrobial resistance (e.g. resistan*, suscept*, surveil*) (Additional file 1: Table S2). The extended search was conducted in October 2017 and updated in March 2019. The search was limited to publications from 1990 onwards; no restrictions on language or filters (e.g. humans) were implemented.
Included studies were required to report quantifiable in vitro antimicrobial susceptibility data for S. Typhi and/or S. Paratyphi A isolated from blood culture, examining at least 10 representative organisms and indicating the study location. Reports from travellers being diagnosed in high-income countries were excluded. Studies with pooled S. Typhi and S. Paratyphi A susceptibility data, studies reporting on isolates from stool culture and duplicate isolates were also excluded.
Prospective and retrospective hospital-, laboratory- and community-based studies were included, if they met the specified inclusion criteria. Review articles were scanned for relevant references. Studies were screened at title, abstract and full-text stage by one author (CD) and reviewed by a second author (AB). Data were extracted into a predefined database by AB and reviewed by BKH and JL. Additionally, 20% of the extracted studies were checked by a third reviewer (CD). Disagreements were resolved by discussion. Susceptibility data for antimicrobials recommended for the treatment of enteric fever by WHO, i.e. ampicillin/amoxicillin, chloramphenicol, trimethoprim-sulphamethoxazole (co-trimoxazole), fluoroquinolones (e.g. ciprofloxacin and ofloxacin), third-generation cephalosporins (e.g. ceftriaxone and cefixime) and azithromycin, were extracted [11 ]. Furthermore, multidrug resistance (MDR; defined as resistance to ampicillin/amoxicillin, chloramphenicol and co-trimoxazole) and nalidixic acid resistance, as a proxy marker for reduced ciprofloxacin susceptibility, were recorded [18 (link)].
Variables extracted included the study start and end dates, patients’ characteristics (age range, mean age, percentage of males, inpatients or outpatients), study design, number of patients screened, number of patients with positive blood culture, antimicrobial susceptibility testing (AST) method and the number (or percentage) of resistant, intermediate and susceptible isolates out of the total number of isolates tested against each antimicrobial. We also recorded case fatalities and clinical outcomes when available. Additionally, the testing standard (e.g. Clinical and Laboratory Standards Institute (CLSI)) and interpretive criteria (including version or year) used to determine resistance, use of internal quality controls and participation in external quality assessments schemes were recorded. The study setting, precise study location, country and GBD study region were recorded for each study. Data were disaggregated by serovar and study location.
We aimed to control for bias and allow for comparison across studies by adhering to the predefined inclusion and exclusion criteria. We expected that there would be differences in the quality of the AST and interpretation of results, reflecting the reality in many LMICs. We adapted a descriptive tool for quality assessment used by Arndt, based on sample size and microbiological testing methodology [23 (link)]. We reviewed the complete description of susceptibility testing methods, which included testing standard, version and/or year (i.e. breakpoints), internal quality controls and external quality assessment. No study was excluded based on this assessment, due to the lack of standardised reporting guidelines for microbiological studies.
Browne A.J., Kashef Hamadani B.H., Kumaran E.A., Rao P., Longbottom J., Harriss E., Moore C.E., Dunachie S., Basnyat B., Baker S., Lopez A.D., Day N.P., Hay S.I, & Dolecek C. (2020). Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Medicine, 18, 1.
Publication 2020
Amoxicillin Ampicillin Azithromycin Blood Culture Cefixime Ceftriaxone Cephalosporins Chloramphenicol Ciprofloxacin Clinical Laboratory Services DNA Library Feces Fluoroquinolones Homo sapiens Inpatient Males Microbicides Multi-Drug Resistance Nalidixic Acid Ofloxacin Outpatients pathogenesis Patients prisma Salmonella typhi Susceptibility, Disease Syringa Trimethoprim-Sulfamethoxazole Combination Typhoid Fever
2
Quantifying Live and Dead Bacteria with SYBR Green/PI Assay
For assaying the live and dead cells in 96-well plates, SYBR Green I and PI were used for double staining of nucleic acids. SYBR Green I (10,000 × stock, Invitrogen) (10 µl) was mixed with 30 µl propidium iodide (20 mM, Sigma) into 1.0 ml of sterile dH2O and vortexed thoroughly. The staining mixture (10 µl) was added to each well and mixed thoroughly. The plate was incubated at room temperature in the dark for 15 minutes. With excitation wavelength at 485 nm, the fluorescence intensities at 535 nm (green emission) and 635 nm (red emission) were measured for each well of the plate using HTS 7000 Plus Bio Assay Reader (PerkinElmer Inc., USA). Meanwhile the B. burgdorferi suspensions (live and 70% isopropyl alcohol killed) in five different proportions of live:dead cells (0∶10, 2∶8, 5∶5, 8∶2, 10∶0) was mixed in wells of 96-well plate. The SYBR Green I/PI was added to each well and the green/red fluorescence ratios were measured for each proportion of live/dead B. burgdorferi using HTS 7000 Plus Bio Assay Reader. With least-square fitting analysis, the regression equation and regression curve of the relationship between percentage of live bacteria and green/red fluorescence ratios were obtained. The regression equation was used to calculate the percentage of live cells in each well.
The MIC (minimum inhibitory concentration) test with the SYBR Green I/PI assay was performed in 96-well microtiter plate with 105 bacteria of B. burgdorferi in fresh BSK-H medium containing doubling concentrations (0.2–50 µg/ml) of various antibiotics doxycycline, amoxicillin, metronidazole, and vancomycin, followed by incubation at 34°C for 6 days when the degree of growth inhibition was measured by the SYBR Green I/PI assay in HTS 7000 Plus Bio assay reader as described above.
Feng J., Wang T., Zhang S., Shi W, & Zhang Y. (2014). An Optimized SYBR Green I/PI Assay for Rapid Viability Assessment and Antibiotic Susceptibility Testing for Borrelia burgdorferi. PLoS ONE, 9(11), e111809.
Publication 2014
Amoxicillin Antibiotics, Antitubercular Bacteria Biological Assay Doxycycline Fluorescence Isopropyl Alcohol Metronidazole Minimum Inhibitory Concentration Nucleic Acids Propidium Iodide Psychological Inhibition Sterility, Reproductive SYBR Green I Vancomycin
3
Diagnostic Strategies for Febrile Illness in Sub-Saharan Africa
We developed a decision tree that begins with ambulatory patients presenting with fever to health facilities in rural sub-Saharan Africa (Fig. 1, Fig. 2, Fig. 3, Fig. 4), and proceeds through diagnosis and treatment to disease outcomes according to the sensitivity and specificity of each diagnostic strategy, the patient's age and malaria prevalence among patients. Typical facilities would include health centres and dispensaries staffed by nurses and perhaps clinical officers, and outpatient departments of district hospitals. Once given first-line treatment, patients were assumed to face the same probabilities, health outcomes and costs regardless of diagnostic method. Parameter estimates for initial diagnosis and treatment were extracted from recently published data. Parameters describing treatment seeking patterns, costs for programme implementation and secondary treatment, and duration of disease were based mainly on those used in previous models.12 ,13 (link) Expert opinion was relied on for probabilities of disease progression and mortality without appropriate treatment where reliable published data do not exist. Parameter values, sources, best estimates and probability distributions representing parameter uncertainty are available at: http://www.wpro.who.int/sites/rdt.
We assumed that health workers used the diagnostic test result in their clinical decision-making and that patients diagnosed positive for malaria received ACT and patients negative for malaria received an antibiotic such as amoxicillin. The proportion receiving antibiotics was varied in the sensitivity analysis. Best (most likely) estimates for drug efficacy were set at 85% for ACT in cases of malaria and 75% for antibiotics in bacterial disease. We assumed that antibiotics were not efficacious for malaria or viral illness, and that antimalarials did not cure bacterial disease. We assumed no coinfection between malaria and bacterial infections. Presumptive treatment on the basis of a history of fever was assumed to have perfect sensitivity and zero specificity. For RDTs we assumed a test detecting histidine-rich protein-2 (HRP-2) specific for P. falciparum, as 90% of malaria in sub-Saharan Africa is P. falciparum, with best estimates for RDT sensitivity and specificity of 96% and 95%, respectively.14 (link)-19 Microscopic diagnosis was based on best standard practice of district-hospital and health-centre general laboratories in sub-Saharan Africa, and assumed best estimates for sensitivity and specificity of 82% and 85%, respectively.20 (link),21 (link) We made comparisons according to all possible levels of endemicity of malaria expressed in terms of prevalence of parasitaemia in febrile outpatients presenting at facilities.
The chances of a febrile episode being fatal are far higher if associated with HIV infection.9 (link),22 (link),23 (link) Very high HIV prevalence would affect the decision tree parameters. To avoid a very complex decision tree structure, parameter values were set assuming that HIV prevalence was relatively low (about 10% of people five years old or over), which is typical outside southern Africa.
We calculated the incremental cost in US dollars (2002 prices) of changing from one diagnostic approach to another from the joint perspective of providers and patients, using the ingredients approach to calculate diagnosis costs, first-line drug costs and variable costs of second-line treatment.24 The costs of microscopy diagnosis included materials, staff time, training and supervision. RDT diagnosis included the unit cost of the test; diagnosis according to presumptive treatment was assumed to cost nothing. We assumed drug cost per adult dose to be US$ 1–2.4 for ACT and US$ 0.61–0.93 for antibiotics. We set the cost of RDT kits at US$ 0.6–1 and that of microscopy at US$ 0.32–1.27. Microscopy costs are dependent on workload and were based on a range of 1000 to 6800 or more diagnoses per year. For simplicity we assumed that microscopy was used only for malaria diagnosis, not for other diseases. All other costs of first-line treatment were excluded as they were assumed to be the same across diagnostic strategies. We included variable costs to providers and patients of any second-line treatment (drugs, reagents, food), but excluded fixed costs (buildings, equipment, supervision and most staff costs) as these would not change with numbers of patients. We assumed that unresolved uncomplicated malaria was treated with a second-line drug of the same price and efficacy as the first-line antimalarial. We assumed that secondary treatment for severe bacterial infection was an alternative antibiotic costing twice as much as first-line treatment. Costs associated with the management of neurological sequelae were excluded.
We measured health outcomes in terms of disability-adjusted life years (DALYs) averted, calculated according to the methods of Lopez et al. without age weights.25 We based life expectancies on a west African life table with a life expectancy at birth of 50 years.
The causes of non-malarial febrile infection vary from region to region and encompass diseases such as acute respiratory infections and bacterial meningitis. For simplicity, disability weights and durations for uncomplicated and severe non-malarial febrile illnesses were assumed to be the same as those for malaria. We assumed that bacterial illness was more likely than malaria to become severe, but that only 5–15% of these infections had bacterial causes, with the rest being self-limiting viral infections.
We did probabilistic sensitivity analysis with Monte-Carlo simulations (Palisade@Risk add-in tool to Microsoft Excel), and cost and health outcomes were generated stochastically (10 000 simulations). Policy-makers will wish to identify interventions that are less costly than the comparator and have better health outcomes, called dominant, and rule out those that are more costly and less effective, termed dominated. More costly and more effective interventions may be selected if they are thought to be good value for money. An intervention was defined as cost-effective if it was dominant or had an incremental cost per DALY averted under US$ 150. The value of US$ 150 was chosen in the base case, to represent a decision-maker's valuation of a healthy year of life. This was based on recommendations of the Ad Hoc Committee on Health Research Priorities, which stated that any intervention costing less than US$ 150 per DALY averted should be considered attractive in low-income countries.26
Additional sensitivity analyses were done by varying the parameter of interest and malaria prevalence according to the ranges in Table 1. A full report of all results is available at: http://www.wpro.who.int/sites/rdt, where customized results specific to local settings can be generated online using an interactive model.
Shillcutt S., Morel C., Goodman C., Coleman P., Bell D., Whitty C.J, & Mills A. (2007). Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bulletin of the World Health Organization, 86(2), 101-110.
Publication 2008
Acute Disease Adult Amoxicillin Antibiotics Antimalarials Bacteria Bacterial Infections Coinfection Diagnosis Disabled Persons Disease Progression Face Fever Food Health Personnel Histidine Hypersensitivity Infection Joints Malaria Meningitis, Bacterial Microscopy Nurses Origin of Life Outpatients Parasitemia Patients Pharmaceutical Preparations Policy Makers Proteins Respiratory Tract Infections sequels Supervision Virus Diseases West African People
4
Development and Validation of Chinese Resident Health Literacy Scale
The Chinese Resident Health Literacy Scale was developed based on a manual published by the Chinese Ministry of Health in 2008—“Basic Knowledge and Skills of People’s Health Literacy” (trial edition) [1 ]. The scale was designed by experts in public health, health education and promotion, and clinical medicine using the Delphi method. Details of the development procedure have been described in a previous paper [44 ]. The scale contains 80 items and three dimensions: (1) knowledge and attitudes; (2) behavior and lifestyle; and (3) health-related skills. The questions cover six aspects: scientific views of health; infectious diseases; chronic diseases; safety and first aid; medical care; and health information. As indicated in Table 1, there are four types of questions in the scale: true-or-false; single-answer (only one correct answer in multiple-choice questions); multiple-answer (more than one correct answer in multiple-choice questions); and situation questions. With multiple-answer questions, a correct response had to contain all the correct answers and no wrong ones. Situation questions were given following a paragraph of instruction or medical information.

Examples of items

Type of itemsExamplesDimensionScope
True-or-false• A01 - Antibiotic is effective in preventing influenza.Knowledge and attitudeInfectious disease
• A07 - Nutrients in vegetables and fruits are similar; so vegetables can be replaced by fruits.Behavior and lifestyleChronic disease
Single-answer• B01 - The integrated conception of health is: (1) Complete physical well-being without disease. (2) Physical and mental well-being. (3) A state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity. (4) I do not know.Knowledge and attitudeScientific views of health
• B36 - When the fire emergency occurs, the correct way to escape is: (1) Encase your head with your arms or cloths and rush out the fire. (2) Wet your cloths and head, or cover yourself with a wet towel and rush out the fire. (3) Flap the fire with you cloths and escape simultaneously. (4) I do not know.Health-related skillsSafety and first aid
Multiple-answer• C06 - Which of the following strategies can prevent chronic disease: (1) Quit smoking and limit the intake of alcohol. (2) Balance the nutrition. (3) Exercise moderately. (4) Be in good mood. (5) I do not know.Knowledge and attitudeChronic disease
• C15 - Which descriptions about health management service for patients with type 2 diabetes are correct: (1) Only patients above 60 years old can receive the service. (2) All diagnosed patients in a community can receive the service. (3) Patients can receive four times of FBG testing for free. (4) Free FBG testing are unlimited, depending on the severity of disease. (5) I do not know.Behavior and lifestyleMedical care
Situation questions• D03 - (A paragraph of instruction book for amoxicillin is given before the question) The drug may cause which of the following adverse reactions: (1) Nausea. (2) Depression. (3) Insomnia. (4) I do not know.Health-related skillsHealth information
• D04 - (A paragraph of introduction to body mass index is given before the question) Mr. Li is 45 years old and 27.7 in BMI (kg/m2). Which of the following categories does he belong to, according to the Chinese adult BMI reference: (1) Obese. (2) Normal. (3) Overweight. (4) I do not know.Health-related skillsHealth information
Before the field study, a survey team was established in each of the 13 cities or counties; the team comprised a principal, a coordinator, four to six investigators, a quality controller, and a data manager. All these team members received training for the sampling method, research tools, and quality control. A simulated survey was conducted during the training, and the investigators’ eligibility was assessed before performing the field survey.
Written informed consent was obtained from all participants before the survey. The scale was self-administered. However, if a participant was unable to complete the scale owing to impaired vision or other such reasons, an interview was used as an alternative. In that situation, the investigators would complete the questions in a neutral fashion on behalf of the participants.
Shen M., Hu M., Liu S., Chang Y, & Sun Z. (2015). Assessment of the Chinese Resident Health Literacy Scale in a population-based sample in South China. BMC Public Health, 15, 637.
Publication 2015
Adult Amoxicillin Antibiotics Arm, Upper Chinese Communicable Diseases Conception Diabetes Mellitus, Non-Insulin-Dependent Disease, Chronic Eligibility Determination Emergencies First Aid Fruit Happiness Head Health Education Health Literacy Health Services Administration Index, Body Mass Influenza Nausea Nutrients Obesity Patients Pharmaceutical Preparations Physical Examination Safety Sleeplessness Surgical Flaps Vegetables
5
Calcium Imaging and DREADD Surgeries in Mice
Mice were anesthetized with 1.5 to 2.0% isoflurane for surgical procedures and placed into a stereotactic frame (David Kopf Instruments, Tujunga, CA). Lidocaine (2%; Akorn, Lake Forest, IL) was applied to the sterilized incision site as an analgesic, while subcutaneous saline injections were administered throughout each surgical procedure to prevent dehydration. In addition, carprofen (5mg/kg) and dexamethasone (0.2mg/kg) were administered both during surgery and for 7 days post-surgery with amoxicillin.
For calcium imaging experiments, mice underwent two separate surgical procedures. First, mice were unilaterally microinjected with 500 nanoliters of AAV1.Syn.GCaMP6f.WPRE.SV40 virus at 50nl/min into the dorsal CA1 using the stereotactic coordinates: −2.1 mm posterior to bregma, 2.0 mm lateral to midline and −1.65 mm ventral to skull surface. Two weeks later, the microendoscope (a gradient refractive index lens) was implanted above the previous injection site. For the procedure, a 2.0mm diameter circular craniotomy was centered 0.5mm medial to the virus injection site. Artificial cerebrospinal fluid (ACSF) was repeatedly applied to the exposed tissue to prevent drying. The cortex directly below the craniotomy was aspirated with a 27-gauge blunt syringe needle attached to a vacuum pump. The microendoscope (0.25 pitch, 0.50 NA, 2.0mm in diameter and 4.79 in length, Grintech Gmbh) was slowly lowered with a stereotaxic arm above CA1 to a depth of 1.35mm ventral to the surface of the skull at the most posterior point of the craniotomy. Next, a skull screw was used to anchor the microendoscope to the skull. Both the microendoscope and skull screw were fixed with cyanoacrylate and dental cement. Kwik-Sil (World Precision Instruments) covered the microendoscope. Two weeks later, a small plastic baseplate was cemented onto the animal’s head atop the previously formed dental cement. Debris was removed from the exposed lens with ddH2O, lens paper and forceps. The microscope was placed on top of the baseplate and locked in a position in which the field of focus was in view, so that cells and visible landmarks, such as blood vessels, appeared sharp and in focus. Finally, a plastic cover was fit into the baseplate and secured by magnets.
For aged DREADD experiments, mice were bilaterally microinjected with 700 nanoliters of Lentivirus CaMK2.hM3Dq.T2A.EGFP/dTomato virus at 100nl/min into the dorsal CA1 using the stereotactic coordinates: −1.80 mm posterior to bregma, +/−1.50 mm lateral to midline, −1.60 mm ventral to skull surface; −2.50 mm posterior to bregma, +/−2.00 mm lateral to midline, −1.70 mm ventral to skull surface.
Cai D.J., Aharoni D., Shuman T., Shobe J., Biane J., Song W., Wei B., Veshkini M., La-Vu M., Lou J., Flores S., Kim I., Sano Y., Zhou M., Baumgaertel K., Lavi A., Kamata M., Tuszynski M., Mayford M., Golshani P, & Silva A.J. (2016). A shared neural ensemble links distinct contextual memories encoded close in time. Nature, 534(7605), 115-118.
Publication 2016
Amoxicillin Analgesics Animals Blood Vessel Calcium, Dietary carprofen Cells Cerebrospinal Fluid Cortex, Cerebral Craniotomy Cranium Cyanoacrylates Dehydration Dental Cements Dexamethasone Forceps Forests Head Isoflurane Lens, Crystalline Lentivirinae Lidocaine Microscopy Mus Needles Operative Surgical Procedures Reading Frames Saline Solution Simian virus 40 Subcutaneous Injections Syringes Tissues Vacuum Virus

Most recents protocols related to «Amoxicillin»

1
Oral Silicic Acid, Antibiotics, and Chlorhexidine Periodontal Treatment
Not available on PMC !

Example 9

    • 6 months oral administration of 10 mg of bioavailable silicic acid per day, in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride, for instance in the form of 2 dosage units
    • combined oral administration of amoxicillin (250 mg three times daily) with metronidazole (250 mg three times daily) during 1 week and
    • Subgingival placement of 2.5 mg chlorhexidine gluconate in a hydrolyzed gelatin matrix chip (PerioChip). The chip degrades within 7-10 days.

It is herein preferable, that the administration of the bioavailable silicic acid and the administration of the antibiotic start simultaneously and concur with the subgingival placement. However, alternative protocols are not excluded.

US11878031B2. Silicic acids for use in the treatment of periodontitis (2024-01-23). Bio Minerals N.V. [BE]. Inventors: Mario Remi Yvonne Calomme [BE], Kathleen Jozef Ingrid Suzanne Van Hoof [BE].
Patent 2024
Acids Administration, Oral Aggressive Periodontitis Amoxicillin Antibiotics chlorhexidine gluconate Choline Choline Chloride DNA Chips Dosage Forms Gelatins Metronidazole Silicic acid
2
Silicic Acid Supplementation and Oral Hygiene
Not available on PMC !

Example 8

    • 6 months oral administration of 10 mg of bioavailable silicic acid per day, in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride;
    • Oral administration of amoxicillin (250 mg three times daily) with metronidazole (250 mg three times daily) during 1 week, and
    • mouth rinsing with chlorhexidine 1% solution twice daily during 4 weeks.

US11878031B2. Silicic acids for use in the treatment of periodontitis (2024-01-23). Bio Minerals N.V. [BE]. Inventors: Mario Remi Yvonne Calomme [BE], Kathleen Jozef Ingrid Suzanne Van Hoof [BE].
Patent 2024
Acids Administration, Oral Aggressive Periodontitis Amoxicillin Chlorhexidine Choline Choline Chloride Metronidazole Silicic acid
3
Gastric MALT Lymphoma Treatment Protocol
The primary therapeutic modalities were determined using the Lugano and Paris staging system (Online Resource 1) and the HPI status. H. pylori eradication was performed in all patients with HPI and localized stage gastric MALT lymphoma. For first-line eradication therapy, a proton pump inhibitor (PPI)-based triple therapy regimen was administered for 2 weeks: PPI (standard dose twice a day), clarithromycin (0.5 g twice a day), and amoxicillin (1 g twice a day). 13C urea breath tests were performed in all patients for 3 months or at least 8 weeks after treatment completion, and at least 2 weeks after PPI withdrawal to confirm HPI eradication. For patients who failed first-line triple therapy, a second-line quadruple-therapy regimen consisting of PPI (standard dose twice a day), tripotassium dicitrato bismuthate (300 mg four times a day), metronidazole (500 mg thrice a day), and tetracycline (500 mg four times a day) was administered for 1–2 weeks.
Patients received radiotherapy, chemotherapy, or chemoradiotherapy if they did not achieve lymphoma regression following first- and second-line HPI eradication therapy, or were at the localized stage without initial HPI, or had advanced-stage gastric MALT lymphoma. For radiotherapy, the clinical target volume included the entire stomach and regional lymph nodes and was prescribed as 30.6 Gy over 17 fractions on the stomach [20 (link)]. The internal target volume (ITV) and planning target volume were set using the motion information obtained from the 4-dimensional CT for assessment of breathing motions and defined as an expansion of 5 mm from the ITV considering the set-up error of the patient [20 (link)]. Patients with the involvement of ≥ 2 organs were excluded from radiotherapy. The R-CVP was the primary systemic chemotherapy regimen, consisting of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, and vincristine 1.4 mg/m2 on day 1, and prednisolone 60 mg/m2 on days 1–5 every 21 days. Localized stage lesions involving small-sized mucosal layers in patients with initial HPI-negative findings could be selectively treated by endoscopic mucosal resection (EMR) and close observation. In the case of chemoradiotherapy, we only used additional radiotherapy for consolidation purposes after chemotherapy by the physicians’ decision. To investigate the side effects of each treatment modality, we reviewed the medical records following the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0.
Min G.J., Kang D., Lee H.H., Kim S.J., Kim T.Y., Jeon Y.W., O J.H., Choi B.O., Park G, & Cho S.G. (2023). Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience. Annals of Hematology, 102(4), 877-888.
Publication 2023
Aftercare Amoxicillin bismuth subcitrate Breath Tests Chemoradiotherapy Clarithromycin Cyclophosphamide Gastric lymphoma Helicobacter pylori Lymphoma Metronidazole Mucous Membrane Nodes, Lymph Patient Participation Patients Pharmacotherapy Physicians Prednisolone Proton Pump Inhibitors Radiotherapy Resection, Endoscopic Mucosal Rituximab Stomach Tetracycline Treatment Protocols Urea Vincristine
4
Optimizing Osteomyelitis and Septic Arthritis Management
This is a monocentric, retrospective, observational, pre-post, quasi-experimental study, set at the Department of Women's and Children's health in Padua, Northern Italy.
Between the end of 2015 and the beginning of 2016, OM/SA internal guidelines were developed by the Division of Pediatric Infectious Diseases and the Pediatric Rheumatology Unit of Padua University Hospital, summarizing international literature evidence. In addition, three training sessions with an overview of the guidelines and treatment rationale were offered to attending physicians and residents.
The impact of the intervention was assessed by comparing the four-year period before OM/SA guidelines implementation (pre-intervention: January 1st, 2012, through December 31st, 2015) to the six years and ten months after intervention (post-intervention: January 1st, 2016, through October 31st, 2022).
According to the implemented guidelines, in fully vaccinated patients older than 3 months, an IV empirical antibiotic therapy is started with a first-generation cephalosporin (cefazolin 150–200 mg/kg/day) for 5–7 days in uncomplicated forms, as the prevalence of MSSA is above 90% in the considered area (7 (link), 8 (link)). The subsequent shift in case of identification of the causative microorganism is to targeted oral therapy, otherwise to an oral antibiotic with the same spectrum activity as the IV therapy (shift from cefazolin to cefalexin or cefuroxime axetil). The total suggested duration of OM treatment is three-four weeks in case of clinical improvement with a normalized C-reactive protein (CRP) before the twentieth day of therapy. The total duration of SA is two-three weeks if isolated, or four weeks in case of associated OM (7 (link)).
Broad-spectrum antimicrobials were defined as: β-lactam and β-lactamase inhibitor combinations, third-generation cephalosporins, clindamycin, glycopeptides, fluoroquinolones, and macrolides. Therapeutic regimens including at least one broad-spectrum prescription, despite the association with amoxicillin or oxacillin, were considered broad-spectrum.
Minotti C., Tirelli F., Guariento C., Sturniolo G., Giaquinto C., Da Dalt L., Zulian F., Meneghel A., Martini G, & Donà D. (2023). Impact of guidelines implementation on empiric antibiotic treatment for pediatric uncomplicated osteomyelitis and septic arthritis over a ten-year period: Results of the ELECTRIC study (ostEomyeLitis and sEptiC arThritis tReatment in children). Frontiers in Pediatrics, 11, 1135319.
Publication 2023
Action Spectrum Amoxicillin Antibiotics beta-Lactamase Inhibitors Cefazolin cefuroxime axetil Cephalexin Cephalosporins Children's Health Clindamycin Communicable Diseases C Reactive Protein Fluoroquinolones Glycopeptides Lactams Macrolides Microbicides Oxacillin Patients Physicians Therapeutics Treatment Protocols
5
Antimicrobial Peptide OaBac5mini Synthesis and Analysis
Antimicrobial Peptides OaBac5mini (N-RFRPPIRRPPIRPPFRPPFRPPVR-C) was prepared via solid-phase synthesis using 9-fluorenylmethoxycarbonyl (F-moc) chemistry at GL Biochem (Shanghai) Ltd. and analyzed by HPLC and MALDI-TOF MS to confirm that the purity was >91.06%.
Amoxicillin, kanamycin, florfenicol, and tetracycline were purchased from China National Institute for Drug and Biological Products Control (Beijing, China). Polymyxin B sulfate (PMB) purchased from Beijing Solarbio Science & Technology co., Ltd (Beijing, China).
Shen S., Sun Y., Ren F., Blair J.M., Siasat P., Fan S., Hu J, & He J. (2023). Characteristics of antimicrobial peptide OaBac5mini and its bactericidal mechanism against Escherichia coli. Frontiers in Veterinary Science, 10, 1123054.
Publication 2023
9-fluorenylmethoxycarbonyl Amoxicillin Antimicrobial Peptide Biological Products florfenicol High-Performance Liquid Chromatographies Kanamycin Pharmaceutical Preparations Polymyxin B Sulfate Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Tetracycline

Top products related to «Amoxicillin»

1
Amoxicillin by Merck Group
Sourced in United States, Germany, United Kingdom, France, Denmark, China, India, Czechia, Italy, Sao Tome and Principe
Amoxicillin is a semi-synthetic antibiotic used in the treatment of bacterial infections. It belongs to the class of penicillin antibiotics and functions by inhibiting cell wall synthesis in susceptible bacteria.
2
Amoxicillin by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Germany, Belgium, Ireland
Amoxicillin is a broad-spectrum antibiotic used in various laboratory applications. It is an effective agent against a wide range of Gram-positive and Gram-negative bacteria. Amoxicillin is commonly used in microbiology, molecular biology, and related fields for research and testing purposes.
3
Mueller hinton agar (mha) by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Italy, Germany, France, India, Spain, China
Mueller-Hinton agar is a microbiological growth medium used for the antimicrobial susceptibility testing of bacteria. It is a standardized agar formulation that supports the growth of a wide range of bacteria and allows for the consistent evaluation of their susceptibility to various antimicrobial agents.
4
Ciprofloxacin by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Germany, Italy, Belgium, Ireland, India
Ciprofloxacin is a synthetic antibiotic that belongs to the fluoroquinolone class. It is a broad-spectrum antimicrobial agent effective against a variety of Gram-positive and Gram-negative bacteria.
5
Ampicillin by Thermo Fisher Scientific
Sourced in United Kingdom, United States, China, Germany, Belgium, Italy, Australia
Ampicillin is an antibiotic that is commonly used in microbiology and molecular biology laboratories. It is a broad-spectrum penicillin-type antibiotic that inhibits the synthesis of bacterial cell walls, effectively killing or preventing the growth of susceptible bacteria.
6
Etest by bioMérieux
Sourced in France, Sweden, United States, Germany, United Kingdom, Denmark, Italy, Australia, Spain, Switzerland, Japan
Etest is a quantitative antimicrobial susceptibility testing (AST) method developed by bioMérieux. It provides minimum inhibitory concentration (MIC) values for specific antimicrobial agents. Etest utilizes a predefined antimicrobial gradient on a plastic strip to determine the MIC of a tested microorganism.
7
Tetracycline by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Germany
Tetracycline is a broad-spectrum antibiotic used in laboratory settings. It functions as an inhibitor of bacterial protein synthesis.
8
Ampicillin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Switzerland, Sao Tome and Principe, Spain, Ireland, India, Italy, Japan, Brazil, Australia, Canada, Macao, Czechia, New Zealand, Belgium, Cameroon, Austria, Israel, Norway, Denmark, Netherlands
Ampicillin is a broad-spectrum antibiotic used in laboratory settings. It is a penicillin-based compound effective against a variety of gram-positive and gram-negative bacteria. Ampicillin functions by inhibiting cell wall synthesis, leading to bacterial cell lysis and death.
9
Gentamicin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Canada, France, Belgium, Switzerland, Italy, Spain, China, Ireland, Israel, Sweden, Austria, Australia, Japan, India, Argentina, Denmark, Netherlands, Macao, Brazil, Portugal, Panama
Gentamicin is a laboratory reagent used for the detection and quantification of the antibiotic gentamicin in biological samples. It is a commonly used tool in research and clinical settings.
10
Erythromycin by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Germany, Macao, Denmark
Erythromycin is a macrolide antibiotic used in various laboratory applications. It functions by inhibiting bacterial protein synthesis. The core function of Erythromycin is to serve as a research tool for studying antibiotic mechanisms and microbial susceptibility.

More about "Amoxicillin"

Amoxicillin is a broad-spectrum beta-lactam antibiotic that belongs to the penicillin class.
It is commonly used to treat a wide range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections.
Amoxicillin is effective against both Gram-positive and Gram-negative bacteria, making it a versatile option for clinicians.
The mechanism of action of Amoxicillin involves interfering with the synthesis of the bacterial cell wall, which ultimately leads to cell death.
This process is crucial in the treatment of bacterial infections, as it helps to eliminate the causative pathogens and alleviate the associated symptoms.
Amoxicillin is generally well-tolerated, but it can cause side effects such as nausea, diarrhea, and rash in some patients.
Proper dosing and duration of therapy are important to ensure the efficacy and safety of Amoxicillin treatment.
Factors such as the specific infection, patient characteristics, and concomitant medications should be considered when determining the appropriate Amoxicillin regimen.
In addition to Amoxicillin, other commonly used antibiotics in the treatment of bacterial infections include Ciprofloxacin, Ampicillin, Tetracycline, Gentamicin, and Erythromycin.
The Etest, a method for determining the minimum inhibitory concentration (MIC) of antibiotics, can be used to guide the selection and dosing of these antimicrobial agents.
PubCompare.ai is a powerful tool that can help optimize Amoxicillin dosing and identify the best treatment protocols from research literature.
By leveraging AI-driven research protocol comparison, clinicians and researchers can locate reproducible and effective Amoxicillin treatments with ease, ultimately improving patient outcomes and advancing the field of pharmaceutical research.